CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1289-1296

  Park, Jin Joo ^a,b   Park, Kyung Woo ^a   Kang, Jeehoon ^a   Jeon, Ki Hyun ^a   Kang, Si Hyuck ^a   Ahn, Hyo Suk ^a   Han, Jung Kyu ^a   Koh, Jin Sin ^a   Lee, Sang Eun ^a   Yang, Han Mo ^a   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Calcium channel blockers; Clopidogrel; CYP3A4; Genetic polymorphisms; On treatment platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 3A4;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG RESPONSE; DYSLIPIDEMIA; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PLATELET REACTIVITY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BLOOD PLATELETS; CALCIUM CHANNEL BLOCKERS; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; TICLOPIDINE;

EID: 84876761052     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0682     Document Type: Article

References (28)

1. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103: 1339-1343.
2. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther 2012; 30: 5-11.
3. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myo infarction. Circulation 2004; 109: 3171-3175.
4. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
5. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38: 92-99.
6. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31: 174-183.
7. Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: Benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol 2010; 63: 60-76.
8. Park KW, Kim HS. Options to overcome clopidogrel response variability. Circ J 2012; 76: 287-292.
9. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 2000; 55: 843-852.
10. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895-1900.
11. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
12. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010; 96: 186-189.
13. Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drugeluting stenting. Am Heart J 2011; 161: 605-610.
14. Olesen JB, Gislason GH, Charlot MG, Fosbol EL, Andersson C, Weeke P, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: A nationwide cohort study. J Am Coll Cardiol 2011; 57: 409-417.
15. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 2008; 52: 1128-1133.
16. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (influence of cilostazol-based triple antiplatelet therapy on ischemic complication after drug-eluting stent implantation) trial. J Am Coll Cardiol 2011; 57: 280-289.
17. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human Mutation 2004; 23: 100.
18. Du J, Yu L, Wang L, Zhang A, Shu A, Xu L, et al. Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta 2007; 383: 172-174.
19. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
20. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
21. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
22. Kim IS, Choi BR, Jeong YH, Kwak CH, Kim S. The CYP2c19*2 and CYP2c19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009; 7: 897-899.
23. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
24. Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004; 26: 192-199.
25. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32: 259-266.
26. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003; 107: 32-37.
27. Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schomig A, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-1902.
28. Lee SP, Bae JW, Park KW, Rha SW, Bae JH, Suh JW, et al. Inhibitory interaction between calcium channel blocker and clopidogrel: Efficacy of cilostazol to overcome it. Circ J 2011; 75: 2581-2589.